



July 15th, 2022

Company Name: GNI Group Ltd.
Representative: Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person: Director, Executive Officer, CFO
Joseph Francis Meyer
(TEL. 03-6214-3600)

F351 Phase II Clinical Trial Results to be Published in *Clinical Gastroenterology and Hepatology*

Beijing Continent Pharmaceutical Co., Ltd. (hereinafter referred to as Beijing Continent), one of the consolidated subsidiaries of GNI Group Ltd. (hereinafter referred to as the Group), has announced yesterday that the paper “Hydronidone for the treatment of liver fibrosis related to chronic hepatitis B: a Phase 2 randomized controlled trial” will be officially published in the American academic journal *Clinical Gastroenterology and Hepatology*.

The Phase II clinical trial of Hydronidone (F351) showed significant histological improvement of liver fibrosis in chronic hepatitis B patients, meeting the primary endpoint and demonstrating a good safety profile. As the Group disclosed on March 17th, 2021, China National Medical Products Administration designated F351 as a “Breakthrough Therapy,” and Phase III clinical trial of F351 commenced in January 2022.

For more details, please refer to the article dated July 14th, 2022 on the Beijing Continent's website below.

<https://www.bjcontinent.com/en/news>

About GNI Group Ltd.

GNI Group is a global healthcare company listed on the Growth Board of the Tokyo Stock Exchange and engaged in drug discovery, pharmaceutical development, biomaterial development, clinical studies, manufacturing, and sales in both the United States and China. For more information, please visit our website below

<https://www.gnipharma.com/>

This document is a press release material created purely for the purpose of publicly disclosing Beijing Continent’s notice on their website and NOT for the purpose of soliciting investment either in Japan or overseas.